Lanvin Group Has Six Months To Lift Its Share Price After NYSE Notice


Date:

(MENAFN- ValueWalk) Lanvin Group said it received a New York Stock Exchange notice on November 10, 2026 for failing the exchange's minimum average closing price standard of US$1.00 per share, and now has six months to cure the deficiency or risk losing its listing.

In its announcement on November 13, the Shanghai- and Milan-based luxury group, which manages the Lanvin, Wolford, Sergio Rossi and St. John Knits brands, said it“is not in compliance with the NYSE's continued listing standard requiring a minimum average closing price of US$1.00 per share for its ordinary shares over a consecutive 30 trading-day period.”

Six-month cure period, monthly checkpoints

The company notified the NYSE within ten business days of its intent to cure the deficiency, as the exchange's rules require. Under those rules, it has a six-month period following the November 10 notice to regain compliance with the price standard.

The clock can stop at any point during that window. Lanvin Group said it can regain compliance if, on the last trading day of any calendar month in the cure period, the shares close at least US$1.00 and the average closing price over the 30 trading days ending that day is also at least US$1.00.

Reverse split is an option, not a decision

The company said it“intends to consider available alternatives, including but not limited to a reverse stock split that is subject to shareholder approval, if necessary to cure the stock price non-compliance.” No split has been proposed here, and any such step would need shareholder approval first.

No immediate effect, shares keep trading

Lanvin Group said the notice has no immediate effect on the continued listing of its ordinary shares and is not anticipated to impact its ongoing business operations. The shares will continue to list and trade on the NYSE under the ticker LANV during the cure period, subject to the exchange's other listing requirements.

The notice adds compliance pressure to a group that filed its Form 20-F annual report for fiscal year 2025 with the SEC on April 30, 2026, and whose average closing price fell below US$1.00 over 30 trading days. The six-month cure period runs from the November 10 notice, giving the company until roughly May 2027 to bring its shares back above the standard.

MENAFN16112026005205011743ID1111968655


ValueWalk

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search